SG11201808592PA - Method for selection of high m6p recombinant proteins - Google Patents

Method for selection of high m6p recombinant proteins

Info

Publication number
SG11201808592PA
SG11201808592PA SG11201808592PA SG11201808592PA SG11201808592PA SG 11201808592P A SG11201808592P A SG 11201808592PA SG 11201808592P A SG11201808592P A SG 11201808592PA SG 11201808592P A SG11201808592P A SG 11201808592PA SG 11201808592P A SG11201808592P A SG 11201808592PA
Authority
SG
Singapore
Prior art keywords
international
new jersey
human lysosomal
cranbury
march
Prior art date
Application number
SG11201808592PA
Inventor
Hung V Do
Russell Gotschall
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of SG11201808592PA publication Critical patent/SG11201808592PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Bioreactor) 600 605 613 (Protein Capturing System) (Chromatography System) 617 609 (Final Product Adjustment) (Chromatography System) => => => 603 (Filtration System) 607 611 (Viral Kill) (Viral Kill) FIG. 6 615 (Filtration System) (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/173059 Al 5 October 2017 (05.10.2017) WIPO I PCT 111111111111110111011111111111010111110 0101111101111111111111110111111111110111111 (51) International Patent Classification: C12N 9/26 (2006.01) (21) International Application Number: PCT/US2017/024981 (22) International Filing Date: 30 March 2017 (30.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/315,400 30 March 2016 (30.03.2016) US 62/457,584 10 February 2017 (10.02.2017) US 15/473,994 30 March 2017 (30.03.2017) US (71) Applicant: AMICUS THERAPEUTICS, INC. [US/US]; 1 Cedar Brook Drive, Cranbury, New Jersey 08512 (US). (72) Inventors: DO, Hung V.; 1 Cedarbrook Drive, Cranbury, New Jersey 08512 (US). GOTSCHALL, Russell; 1 Cedar Brook Drive, Cranbury, New Jersey 08512 (US). (74) Agent: ALEGRIA, Rory P.; Servilla Whitney LLC, 33 Wood Avenue South, Suite 830, Iselin, New Jersey 08830 (US). — (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) = (54) Title: METHOD FOR SELECTION OF HIGH M6P RECOMBINANT PROTEINS (57) : Methods for the production, capturing and purification of recombinant human lysosomal proteins are described. Such recombinant human lysosomal proteins can have high content of mannose-6-phosphate residues. Also described are pharmaceutical compositions comprising such recombinant human lysosomal proteins, as well as methods of treatment and uses of such recombin- ant human lysosomal proteins. W O 20 1717 / 305 9 Al
SG11201808592PA 2016-03-30 2017-03-30 Method for selection of high m6p recombinant proteins SG11201808592PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662315400P 2016-03-30 2016-03-30
US201762457584P 2017-02-10 2017-02-10
US15/473,994 US10227577B2 (en) 2016-03-30 2017-03-30 Method for selection of high M6P recombinant proteins
PCT/US2017/024981 WO2017173059A1 (en) 2016-03-30 2017-03-30 Method for selection of high m6p recombinant proteins

Publications (1)

Publication Number Publication Date
SG11201808592PA true SG11201808592PA (en) 2018-10-30

Family

ID=58640993

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808592PA SG11201808592PA (en) 2016-03-30 2017-03-30 Method for selection of high m6p recombinant proteins

Country Status (13)

Country Link
US (3) US10227577B2 (en)
JP (2) JP7046003B2 (en)
KR (3) KR102455821B1 (en)
AU (2) AU2017239640B2 (en)
BR (1) BR112018070189A2 (en)
CA (1) CA3019354A1 (en)
CL (1) CL2018002767A1 (en)
IL (2) IL262060B (en)
MX (3) MX2018011951A (en)
PE (1) PE20190127A1 (en)
SG (1) SG11201808592PA (en)
WO (1) WO2017173059A1 (en)
ZA (2) ZA201807184B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102618519B1 (en) * 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 Formulations comprising recombinant acid alpha-glucosidase
AU2017239640B2 (en) * 2016-03-30 2022-07-28 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
EP3568152A1 (en) * 2017-01-10 2019-11-20 Amicus Therapeutics, Inc. Recombinant alpha-galactosidase a for treatment of fabry disease
LT3624831T (en) * 2017-05-15 2023-07-10 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
BR112022004000A2 (en) 2019-09-06 2022-05-31 Amicus Therapeutics Inc Method for capturing and purifying biologicals
EP3871687A1 (en) * 2020-02-27 2021-09-01 eleva GmbH Enzyme replacement therapy for treating pompe disease
WO2023150387A1 (en) * 2022-02-07 2023-08-10 M6P Therapeutics, Inc. Compositions comprising acid alpha glucosidase and methods of use thereof
TW202400212A (en) * 2022-05-05 2024-01-01 美商阿米庫斯醫療股份有限公司 Methods for treating pompe disease

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
US4985445A (en) 1988-02-12 1991-01-15 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitors and novel compounds
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5011829A (en) 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US20020073438A1 (en) * 1995-08-02 2002-06-13 Reuser Arnold J. Methods of purifying human acid alpha-glucosidase
US20020013953A1 (en) * 1995-08-02 2002-01-31 Reuser Arnold J. Compositions and methods for treating enzyme deficiency
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
EP1030839B1 (en) 1997-11-10 2004-02-04 G.D. SEARLE & CO. Use of alkylated iminosugars to treat multidrug resistance
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
ES2312222T3 (en) 1998-12-07 2009-02-16 Genzyme Corporation POMPE DISEASE TREATMENT.
EP1165080A2 (en) 1999-02-12 2002-01-02 G.D. SEARLE & CO. Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
DE60001745T2 (en) 1999-07-26 2004-03-04 G.D. Searle & Co., Chicago USE OF LONG-CHAIN N-ALKYL DERIVATIVES OF DEOXYNOJIRIMYCIN WITH GLUCOCEREBROSIDASE ENZYMES FOR PRODUCING A MEDICINE FOR TREATING DISEASES RELATING TO GLYCOLIPID ACCUMULATION
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
PT1782825E (en) 2000-07-18 2014-11-04 Univ Duke Treatment of glycogen storage diseases type ii
CN1638739A (en) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 Compound for treating assuetude disturbance
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
WO2002087510A2 (en) 2001-04-30 2002-11-07 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
CN1604788B (en) 2001-10-16 2013-04-17 里克斯金蒂克斯公司 High-concentration protein formulations and method of manufacture
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
DK2441467T3 (en) 2003-01-31 2015-08-31 Sinai School Medicine Combination therapy for the treatment of protein deficiency disorders
FR2861991B1 (en) 2003-11-07 2008-01-18 Centre Nat Rech Scient USE OF GLUCOSIDASE INHIBITORS FOR MUCOVISCIDOSE THERAPY
AU2005211775B2 (en) * 2004-02-06 2009-10-08 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
US20050244400A1 (en) 2004-02-10 2005-11-03 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
EP1896083B1 (en) * 2005-05-17 2016-03-02 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
AU2007322123A1 (en) 2006-11-13 2008-05-29 Biomarin Pharmaceutical Inc. Methods for treating Pompe disease
WO2008112525A2 (en) 2007-03-09 2008-09-18 Link Medicine Corporation Treatment of lysosomal storage diseases
EP2150254A4 (en) 2007-04-26 2010-11-10 Amicus Therapeutics Inc Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2009066069A1 (en) 2007-11-21 2009-05-28 Summit Corporation Plc Treatment of protein folding disorders
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
EP2946785B1 (en) 2008-02-12 2018-10-24 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
US20110189710A1 (en) 2008-03-12 2011-08-04 Amicus Therapeutics, Inc. TREATMENT OF POMPE DISEASE WITH SPECIFIC PHARMACOLOGICAL CHAPERONES AND MONITORING TREATMENT USING SURROGATE MARkERS
MX2010009875A (en) 2008-03-12 2010-11-26 Amicus Therapeutics Inc Assays for diagnosing and evaluating treatment options for pompe disease.
US20110237538A1 (en) 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010056746A1 (en) 2008-11-11 2010-05-20 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
WO2010075010A2 (en) 2008-12-16 2010-07-01 Genzyme Corporation Oligosaccharide-protein conjugates
NZ595629A (en) 2009-04-09 2013-04-26 Amicus Therapeutics Inc Methods for preventing and/or treating lysosomal storage disorders
WO2010148253A2 (en) 2009-06-17 2010-12-23 Zystor Therapeutics, Inc. Formulations for lysosomal enzymes
CN104651428A (en) * 2009-09-29 2015-05-27 根特大学 Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
US20130196410A1 (en) 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
WO2012042386A2 (en) * 2010-09-29 2012-04-05 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
SG194486A1 (en) 2011-04-22 2013-12-30 Genzyme Corp Modified acid alpha glucosidase with accelerated processing
WO2013013017A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
US20150258081A1 (en) 2011-12-22 2015-09-17 Centogene Ip Gmbh Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
WO2013134530A1 (en) 2012-03-07 2013-09-12 Amicus Therapeutics, Inc. High concentration alpha-glucosidase compositions for the treatment of pompe disease
BR112014022624A2 (en) 2012-03-15 2017-07-11 Oxyrane Uk Ltd Methods and Materials for Treatment of Pompe Disease
EP3871688B1 (en) 2012-05-03 2024-03-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of pompe disease
AU2013273473B2 (en) 2012-06-06 2016-05-26 Consiglio Nazionale Delle Ricerche Allosteric chaperones and uses thereof
BR112017005810A2 (en) 2014-09-30 2018-02-27 Amicus Therapeutics Inc Highly potent acid alpha-glucosidase with enhanced carbohydrates
AU2017239640B2 (en) * 2016-03-30 2022-07-28 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins

Also Published As

Publication number Publication date
KR102343162B1 (en) 2021-12-23
JP2022101545A (en) 2022-07-06
JP7046003B2 (en) 2022-04-01
AU2017239640A1 (en) 2018-10-25
CA3019354A1 (en) 2017-10-05
US10227577B2 (en) 2019-03-12
US20190382742A1 (en) 2019-12-19
US11441138B2 (en) 2022-09-13
IL262060B (en) 2022-09-01
US20230079225A1 (en) 2023-03-16
IL262060A (en) 2018-11-29
IL295551A (en) 2022-10-01
KR20180128945A (en) 2018-12-04
MX2022014533A (en) 2022-12-13
AU2022259797A1 (en) 2022-12-01
MX2022014532A (en) 2022-12-13
US20170335301A1 (en) 2017-11-23
WO2017173059A1 (en) 2017-10-05
KR102455821B1 (en) 2022-10-18
JP7436545B2 (en) 2024-02-21
PE20190127A1 (en) 2019-01-17
KR20220145918A (en) 2022-10-31
CL2018002767A1 (en) 2019-01-11
KR20210157477A (en) 2021-12-28
MX2018011951A (en) 2019-02-13
JP2019509754A (en) 2019-04-11
BR112018070189A2 (en) 2019-02-19
AU2017239640B2 (en) 2022-07-28
ZA202006604B (en) 2023-04-26
ZA201807184B (en) 2021-02-24

Similar Documents

Publication Publication Date Title
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201806002SA (en) Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process
SG11201807912SA (en) Vaccine against rsv
SG11201809700YA (en) Gdf15 fusion proteins and uses thereof
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201805162VA (en) Plasmid constructs for heterologous protein expression and methods of use
SG11201803958WA (en) Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201805001UA (en) Method of treating influenza a
SG11201807134RA (en) Transposon system and methods of use
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof